ARIAD presents new preclinical data on ponatinib
The Fly on the Wall
Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Seeking Alpha
Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine
TheStreet.com
The Survey Says: Ariad's Leukemia Drug Is Toxic
TheStreet.com
Ariad Pharma Falls On Weak Leukemia Drug Prescriptions
TheStreet.com
3 Biotechs Still Burning Through Cash: Ariad Pharmaceuticals, Inc., Dynavax Technologies Corporation, MannKind Corporation
Insider Monkey
3 Biotechs Still Burning Through Cash
Motley Fool